局部晚期鼻咽癌的最佳治疗是什么?个体患者数据网络Meta分析
该研究基于鼻咽癌化疗Meta分析数据库的个体患者数据,纳入20项随机试验共5,144例非转移性鼻咽癌患者,采用频率学网络Meta分析比较七类治疗方案。结果显示,同步放化疗后辅助化疗(CRT-AC)在总生存上获益概率最高,CRT-AC相比单纯放疗的HR为0.65(95%CI 0.56-0.75),且对全部终点均有改善;诱导化疗后同步放化疗(IC-CRT)对远处控制效果最佳。
要点
- CRT-AC对总生存获益概率最高,相比单纯放疗HR 0.65(95%CI 0.56-0.75)
- CRT-AC相比CRT的总生存HR为0.85(95%CI 0.68-1.05),无进展生存HR为0.81(95%CI 0.66-0.98)
- 化疗方案越多,急性毒性风险越高
核心结论
- 在同步放化疗基础上加辅助化疗(CRT-AC)获得最高生存获益,且对全部终点均有持续改善。
- 在同步放化疗基础上加诱导化疗(IC-CRT)对远处控制效果最高。
研究设计与样本
- 个体患者数据网络Meta分析,数据来自鼻咽癌化疗Meta分析数据库。
- 纳入20项非转移性鼻咽癌放疗联合或不联合化疗的随机试验,共5,144例患者。
- 治疗方案分为七类:单纯放疗(RT)、诱导化疗后放疗(IC-RT)、放疗后辅助化疗(RT-AC)、诱导化疗后放疗再辅助化疗(IC-RT-AC)、同步放化疗(CRT)、诱导化疗后同步放化疗(IC-CRT)、同步放化疗后辅助化疗(CRT-AC)。
- 采用P-score对治疗排序,应用固定效应和随机效应频率学网络Meta分析模型。
主要发现
- 总生存获益概率最高的三种治疗依次为CRT-AC、CRT和IC-CRT,相比单纯放疗的HR(95%CI)分别为0.65(0.56-0.75)、0.77(0.64-0.92)和0.81(0.63-1.04)。
- CRT-AC相比CRT的总生存、无进展生存、局部区域控制和远处控制的HR(95%CI)分别为0.85(0.68-1.05)、0.81(0.66-0.98)、0.70(0.48-1.02)和0.87(0.61-1.25)。
- IC-CRT在无进展生存上排名第二,在远处控制上排名第一。
- CRT从未排名第一。
- CRT相比IC-CRT的总生存、无进展生存、局部区域控制和远处控制的HR(95%CI)分别为0.95(0.72-1.25)、1.13(0.88-1.46)、1.05(0.70-1.59)和1.55(0.94-2.56)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose The role of adjuvant chemotherapy (AC) or induction chemotherapy (IC) in the treatment of locally advanced nasopharyngeal carcinoma is controversial. The individual patient data from the Meta-Analysis of Chemotherapy in Nasopharynx Carcinoma database were used to compare all available treatments. Methods All randomized trials of radiotherapy (RT) with or without chemotherapy in nonmetastatic nasopharyngeal carcinoma were considered. Overall, 20 trials and 5,144 patients were included. Treatments were grouped into seven categories: RT alone (RT), IC followed by RT (IC-RT), RT followed by AC (RT-AC), IC followed by RT followed by AC (IC-RT-AC), concomitant chemoradiotherapy (CRT), IC followed by CRT (IC-CRT), and CRT followed by AC (CRT-AC). P-score was used to rank the treatments. Fixed- and random-effects frequentist network meta-analysis models were applied. Results The three treatments with the highest probability of benefit on overall survival (OS) were CRT-AC, followed by CRT and IC-CRT, with respective hazard ratios (HRs [95% CIs]) compared with RT alone of 0.65 (0.56 to 0.75), 0.77 (0.64 to 0.92), and 0.81 (0.63 to 1.04). HRs (95% CIs) of CRT-AC compared with CRT for OS, progression-free survival (PFS), locoregional control, and distant control (DC) were, respectively, 0.85 (0.68 to 1.05), 0.81 (0.66 to 0.98), 0.70 (0.48 to 1.02), and 0.87 (0.61 to 1.25). IC-CRT ranked second for PFS and the best for DC. CRT never ranked first. HRs of CRT compared with IC-CRT for OS, PFS, locoregional control, and DC were, respectively, 0.95 (0.72 to 1.25), 1.13 (0.88 to 1.46), 1.05 (0.70 to 1.59), and 1.55 (0.94 to 2.56). Regimens with more chemotherapy were associated with increased risk of acute toxicity. Conclusion The addition of AC to CRT achieved the highest survival benefit and consistent improvement for all end points. The addition of IC to CRT achieved the highest effect on DC.
引用
- Ribassin-Majed L, Marguet S, Lee AWM, et al. What Is the Best Treatment of Locally Advanced Nasopharyngeal Carcinoma? An Individual Patient Data Network Meta-Analysis. J Clin Oncol. 2016. PMID: 27918720. doi:10.1200/JCO.2016.67.4119
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。